Do FDA approvals matter as much for medtech as biotech?

I’m pretty new to healthcare investing and I’ve got about **$5,000 in AI/ML Innovations Inc. ($AIML)**, so I’m trying to understand how regulatory stuff usually plays out. AIML is more on the **medtech / medical AI** side with ECG and cardiac monitoring tools. They’ve talked about working through **Health Canada** approvals and eventually **FDA pathways** in the U.S. In biotech, FDA approvals seem to move stocks a lot. For medtech companies like this, do approvals usually have the same impact, or does the market care more about what happens after approval, like adoption and contracts? Would love to hear how others here think about this.